

4th November 2010

BIOMNIS ANNOUNCES €3 MILLION INVESTMENT IN THE IRISH MARKET

Biomnis, the leader in medical testing and specialised medical pathology, has today (4th November 2010) announced an investment of approximately €3 million in the Irish pathology sector. The investment includes the acquisition of Euromedic Lablink Ltd, a company owned by Euromedic B.V., and the introduction of a new suite of medical tests in Ireland by Biomnis' Irish subsidiary, Claymon Biomnis.

Euromedic Lablink will now join forces with Claymon Biomnis to create a new enlarged group, Biomnis Ireland. As a result of the acquisition, Biomnis Ireland will also become the largest workplace health screening provider in the Irish market.

Biomnis is beginning a major test repatriation scheme to Ireland which will see a suite of test processes transferred from Biomnis labs in France to the Irish laboratory, based at Sandyford in Co. Dublin. The company will also conduct a significant technology upgrade as part of the deal, which will lead to 30% increase in the amount of testing currently carried out within their Dublin laboratories.

The deal is the first major consolidation within the independent medical laboratory services sector creating the largest private provider in the Irish market. Biomnis Ireland is wholly owned by the Biomnis Group which is one of the top three European medical laboratory groups, processing more than ten million specialised tests annually, for clients in 40 countries throughout the world.

Speaking at the announcement; John O'Sullivan, MD of Biomnis Ireland, said: *"This deal represents a vote of confidence in Ireland by one of the largest European medical testing groups. Claymon Biomnis has established a significant presence in the Irish laboratory testing sector over the last nineteen years through the successful development of strong partnerships with many public and private hospitals and clinics throughout the country. The acquisition of Euromedic Lablink, a recognised medical testing service provider in Ireland since 2001, is a natural fit and will allow us to capitalise on the synergies between our two companies. It will also allow the*

newly formed group, Biomnis Ireland, to greatly enhance and broaden its service offering to health care professionals in both the public and private sectors.

The additional investment by Biomnis in the Irish market as well as their decision to transfer to our laboratory a suite of test processes, such as Vitamin D Analysis, Autoimmune Serology and Allergy Testing, which are typically carried out at their state of the art laboratories in France, also illustrates the group's confidence in Ireland as an investment location. These two developments recognise both the highly-skilled and educated workforce that continue to make Ireland an attractive destination to locate as well as the opportunities that exist in this specialised sector to expand and grow now and into the future.

As more than 70% of all decisions about patient diagnosis rest on medical test results, our core purpose has always been to help healthcare professionals diagnose, monitor and treat patient illness. We are very excited that as Biomnis Ireland we can play an increasingly prominent role in the fight against human disease."

The announcement was today welcomed by the Minister for Enterprise, Trade and Innovation, Batt O'Keeffe TD.

'Biomnis is a world-renowned French firm with a strong track record in product innovation. The acquisition of Euromedic Lablink, coupled with the decision to locate test procedures in Dublin and significantly upgrade their technology capability, dramatically strengthens Biomnis Ireland's clinical expertise here. Biomnis Ireland is now well positioned for strong growth in the pathology and health screening sectors here and I wish the firm every success,' said Minister O'Keeffe.

The newly formed Biomnis Ireland will employ over 100 people at their laboratories in Dublin. All existing contracts with customers of Lablink and Claymon Biomnis will be maintained and continued as the group looks forward to servicing the current and future needs of healthcare professionals in Ireland.

Notes to the Editor:

Claymon Biomnis has been supporting health care professionals in Ireland since it was founded in 1991. Located in Sandyford, Dublin their 12,000 square foot

laboratory processes more than one and a half million tests a year for over 1400 clients including public and private hospital/clinics and many private organisations throughout Ireland.

In 1999, Claymon Biomnis Laboratories became proud members of the prestigious Biomnis Group which was founded more than a century ago by Marcel Mérieux, a protégé of Louis Pasteur.

Biomnis is one of the top three European medical laboratory groups, processing more than 10 million tests annually, for clients in 40 countries throughout the world. With revenues of nearly a quarter of a billion euro a year, Biomnis employs 60 full time medical pathologists and over 1,600 scientific, technical and support staff.

Lablink was established in April 2001 with a commitment to provide a unique streamlined clinical laboratory through a systematic approach. It provides a complete service encompassing all aspects of laboratory analysis from collection of samples to reporting.

For further information:

Iarla Mongey/Martha Kavanagh
Drury
087 235 6461 / 087 6462006

Noel McNally
Biomnis Ireland
086 049 6655